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Objectives: The aim of this study was to evaluate the opioid response
in patients receiving morphine and pregabalin, independently from
the presumed pain mechanisms, in comparison with patients re-
ceiving morphine treatment only.
Methods: A multicenter prospective randomized controlled study
was carried out in a sample of 70 advanced cancer patients with
pain requiring strong opioids. Thirty-ﬁve patients (group MO) were
randomized to receive sustained-release morphine using initial doses
of 60 mg/day. Thirty-ﬁve patients (group MO-PR) were randomized
to start the same morphine doses and pregabalin in increasing
doses, starting with 25 mg/day up to 150 mg/day in one week. The
following data were also recorded before starting the treatments
(T0) and then at week intervals for four weeks (W1-4): age, gender,
primary cancer and known metastases, pain causes and mecha-
nisms, symptoms associated with opioid therapy, pain intensity,
Brief Pain Inventory (BPI), morphine doses and escalation indexes
(OEIs), and quality of life.
Results: Forty-eight patients completed the study, twenty-eight and
sixteen patients in group MO and MO-PR, respectively. Twenty
patients were females, the mean age was 65.5 (±10.3), and the mean
Karnofsky status was 66.0 (±18.9). No diﬀerences between groups
were found in age (P=0.839), Karnofsky status (P=0.741),
opioid doses as well as escalation indexes (OEI mg, P=0.260, and
OEI%, P=0.270). No diﬀerences between the two groups were
found in quality of life and all BPI items.
Conclusion: The use of low doses of pregabalin added to morphine
therapy in advanced cancer patients does not seem to provide ad-
vantageous analgesic eﬀects, despite limitations of the present study
due to the number of drop-outs.
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Cancer pain is a major clinical problem in patients withmetastases. Like other chronic pain states, cancer pain
involves sensitization of central neurons, associated with a
hyperactivity of N-methyl D-aspartate (NMDA)-type re-
ceptors. Other than oncological treatment for the primary
disease, the current analgesic treatment includes speciﬁc
measures, principally based on the guidelines provided by
World Health Organization: a sequential approach of an-
algesics, step by step, according to the potency of drugs
associated with adjuvants. Patients with moderate-to-severe
pain are candidates to start strong opioids.1 Gabapentin
has been used clinically for neuropathic cancer pain as an
adjuvant agent.2–4 Recent reports have identiﬁed synergistic
eﬀects of gabapentic-like compounds, NMDA receptor
antagonists, and opioids, because of the inhibition of af-
ferent glutamate release. Diﬀerent experimental models
have shown the role of gabapentinoids in states of spinal
cord hyperexcitation. NMDA hyperactivity is also involved
in the development of tolerance and hyperalgesia to chronic
treatment with opioids,5 states of spinal hyperexcitability in
cancer-induced bone pain,6 and visceral hypersensitive
states.7 A combination of morphine and gabapentin re-
sulted in enhanced inhibitory eﬀects on the evoked ﬁring of
dorsal horn neurons in a rat model of neuropathy.8
Experimental models have shown that bone pain, which
is clinically associated with bone metastases and movement-
induced pain, produce central sensitization leading to hyper-
algesia, allodynia, and decreased response to opioids, in
comparison with inﬂammatory models.9 In a case series, the
addition of gabapentin in low doses was associated with sig-
niﬁcant improvement of incident pain exacerbated by move-
ment,10 in patients with a presumably spinal hyperexcitatory
state.
Pregabalin has a favorable pharmacokinetic proﬁle
compared with gabapentin.11,12 As with gabapentin, pre-
gabalin is inactive at gamma-aminobutyric acid a and
gamma-aminobutyric acid b receptors, with the main site of
action being the a2-d subunit of presynaptic, voltage-
dependent calcium channels. As upregulation of the a2-d
subunit may play an important role in hypersensitization
processes, pregabablin appears to play a potential role in
inhibiting the modulation of neuronal excitability.13 Pre-
gabalin dosing aimed at the optimal balance of eﬃcacy and
tolerability provided signiﬁcant pain relief and reduced the
risk of adverse eﬀects and therapy discontinuation.14 The
potential usefulness of calcium-channel ligands in combi-
nation with opioids is suggested by data from research and
clinical trials.15
According to these observations the association of
opioid therapy and pregabalin could be helpful in im-
proving opioid analgesia, also braking the tendency to es-
calate the opioid doses in a long-term period, which could
result in an increase of opioid-related adverse eﬀects, other
than the development of opioid-induced hyperalgesia.
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Relatively low doses of adjuvants may be better tolerated
providing an opioid-sparing analgesia, according to their
putative antihyperalgesic eﬀects.16
The aim of this study was to evaluate the opioid re-
sponse in patients receiving morphine and pregabalin, in-
dependently from the presumed pain mechanisms, in
comparison with patients receiving morphine treatment only.
PATIENTS AND METHODS
A multicenter prospective randomized controlled study
was carried out in a sample of 70 advanced cancer patients
with pain requiring strong opioids, who had received opioids
for mild-to-moderate pain, including tramadol and codeine
at doses of at least 300mg and 180mg, respectively, un-
successfully. Patients with relevant coexisting liver or renal
disease, cognitive impairment, an expected survival <3
months, requiring radiotherapy, or a new course of chemo-
therapy, with a prevalent incident pain component were ex-
cluded. The study was approved by the Local Ethical
Committee of the University of Palermo, and adhered to
Helsinki declaration (Eudract number 2008-005954-19).
Randomization was computer-generated. Thirty-ﬁve
patients (group MO) were randomized to receive sustained-
release morphine using initial doses of 60mg/d. Thirty-ﬁve
patients (group MO-PR) were randomized to start the same
morphine doses and pregabalin in increasing doses, starting
with 25mg/d up to 150mg/d in 1 week. Oral morphine was
provided in doses of about 1/6 of their 24-hour oral morphine
equivalent requirement, as breakthrough pain medication.
Doses were computed in the following days if >2 extradoses
were required, according to department policy.17 The sub-
sequent dosages of oral morphine were changed to obtain an
adequate balance between acceptable analgesia and tolerable
adverse eﬀects. The doses of pregabalin were also increased
according to the protocol, but a ﬂexible use14,18 was allowed to
ﬁnd “the best tolerated dose” within a week. The use of other
drugs was allowed, including ones generally administered in
palliative care to manage symptoms. Patients already receiving
nonopioid analgesics or steroids could continue their treat-
ment, while all drugs with a putative analgesic eﬀect, coa-
nalgesics such as antidepressants or other anticonvulsants,
were proscribed. All patients were strictly monitored by fre-
quent phone contacts and regular visits. Patients with a poor
opioid response, because of the prevalence of adverse eﬀects,
despite symptomatic treatment, were switched to an alter-
native opioid, and were withdrawn from the study.
The following data were also recorded before starting
the treatments (T0) and then at weekly intervals for 4 weeks
(W1 to W4). An extension period was also planned with a
further evaluation after 8 weeks (W8), whenever possible:
 Age, sex, primary cancer and known metastases, pain
causes and mechanisms on the basis of clinical history,
known metastases, physical examination, and available
investigations.
 Symptoms associated with opioid therapy, such as nausea
and vomiting, drowsiness, and confusion, were recorded
(assessed by patients), using a scale from 0 to 3 (not at all,
slight, a lot, severe), unless for constipation, which was
rated by the following scale used, according to monitoring
policy at our institution: 0=1 passage/1 to 2 days, 1=1
passage/3 to 4 days, 2=1 passage>4 days, 3=rectal
measures.16
 Pain intensity, measured using the patient’s self report on
a numerical 0 to 10 scale.
 A Brief Pain Inventory (BPI) at the diﬀerent intervals.
 From the opioid starting dose (OSD), 60mg/d of morphine
at referral, and the doses administered 4 weeks after (opioid
maximum dose, the OEI as a percentage (OEI%) was
calculated according to the following formula: [(opioid
maximum doseOSD)/OSD]/days100.19
 At inclusion, on the basis of the patient’s history, clinical
examination performed by an expert physician with
experience in neurological examination in cancer pa-
tients, and results from recent neuroimaging examina-
tions, were collected. Patients were classiﬁed into tertiles
based on ascending ratings of diagnostic certainty by
clinicians, with graded evidence of nervous system lesion,
and labeled as deﬁnite neuropathic pain (NP), possible
NP, or unlikely NP,16,20 according to the criteria for
clinical classiﬁcation of suspected NP suggested by
Rasmussen et al21 and instrumental ﬁndings.
 Doses of pregabalin tolerated at the diﬀerent time
intervals chosen.
 Quality of life was evaluated by the Spitzer QoL Index,
which is a cancer-speciﬁc measurement. The score was
calculated after answering the 5 items, rated on a Likert
3-point scale (0 to 2) in the areas of activity, daily life,
health perceptions, social support, and behavior.22
Statistical Analysis
A power analysis indicates that a sample size of 25
patients per group would allow the detection of a 20%
diﬀerence (P<0.05, power=0.8). This computation
assumes that the mean diﬀerence is 0.20 with a 95% con-
ﬁdence interval of 0.07 to 0.33 and the common within-
group SD of 0.28. Frequency analysis was performed with
w2 test. The univariate repeated measures analysis (analysis
of variance) and the paired Wilcoxon signed-rank test were
used to compare the means or the scores of parametric or
nonparametric variables, respectively, at the diﬀerent time
intervals. The 1-way analysis of variance and Mann-Whit-
ney U statistic test were used to compare the diﬀerent
parametric or nonparametric variables. All P values were
2-sided and P values <0.05 were considered statistically
signiﬁcant.
RESULTS
Ten patients (1 and 9 patients in groups MO and MO-
PR, respectively) did not start the study after random-
ization, because they withdrew their consent to participate.
Of the remaining 60 patients, 48 patients completed the
study, 30 and 18 patients in groups MO and MO-PR, re-
spectively. Twelve patients did not complete the study be-
cause they were lost to follow-up. Of them, in group MO, 2
patients died, 1 patient was admitted for melena and then
switched to other opioids, and 1 patient was switched to
another opioid. In group MO-PR, 3 patients died, 2 pa-
tients discontinued pregabalin because of adverse eﬀects
(leg edema and drowsiness, respectively), and 1 patient
droppedout for poor compliance.
Of the 48 patients, 28 and 16 patients in groups MO and
MO-PR, respectively, were followed for the entire period of
study (W4), and 22 patients and 14 patients, respectively, for
the extension up to W8. Twenty patients were female, the
mean age was 65.5 (±10.3) years, and the mean Karnofsky
status was 66.0 (±18.9). No diﬀerences between groups were
found in age (P=0.839), Karnofsky status (P=0.741),
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opioid doses, and the calculated escalation indexes (OEImg,
P=0.260, and OEI%, P=0.270). Eight and 2 patients in
groups MO and MO-PR, respectively, had “deﬁnite”
neuropathic pain. This low number of patients did not allow
a further subgroup analysis.
Data on pain and symptom intensity, morphine and
pregabalin doses, and OEI are reported in Table 1. No
statistical diﬀerences were observed. No diﬀerences between
the 2 groups were found in quality of life and all BPI items
(Table 2). In a subgroup analysis, 10 patients (8 and 2 pa-
tients in groups MO and MO-PR, respectively) had a def-
inite neuropathic pain. As expected, this did not indicate a
signiﬁcant diﬀerence (Pearson w2, 4.551). No diﬀerences in
the number of patients receiving adjuvant or symptomatic
drugs were found between the 2 groups.
DISCUSSION
Pregabalin plays a potential role in reducing pain,
providing better analgesia in association with morphine in
the management of cancer pain in advanced cancer pa-
tients. Gabapentinoids selectively reduced C-ﬁber-evoked
ﬁeld potentials after induction of long-term potentiation, sug-
gesting that a combination of lower doses of gabapentinoids
TABLE 1. Pain, Symptom Intensity, and Opioid Doses in Groups MO-PR and MO (See Text) Before Starting Opioids (T0), at Weekly
Intervals (W1, W2, W3, W4), and After 8 Weeks
T0 W1 W2 W3 W4 W8
N points
MO-PR 18 18 17 17 16 14
MO 30 30 30 30 28 22
Pain
MO-PR 7.0 (1.2) 3.2 (1.9)* 2.7 (1.9)* 3.4 (2.3)* 3.5 (1.9)* 3.3 (2.3)*
MO 7.1 (1.6) 4.0 (1.7)* 3.6 (1.9)*w 3.1 (1.7)*w 2.7 (1.8)*w 2.9 (1.6)*w
P 0.839 0.190 0.146 0.937 0.285 0.702
Nausea
MO-PR 1.0 (1.1) 0.7 (0.9) 0.5 (0.8) 0.7 (0.9) 0.3 (0.4)*w 0.6 (0.8)
MO 0.5 (0.8) 0.6 (0.8) 0.5 (0.8) 0.3 (0.5) 0.3 (0.5) 0.1 (0.3)w
P 0.075 0.631 0.864 0.120 0.755 0.038
Vomiting
MO-PR 0.2 (0.6) 0.2 (0.8) 0.3 (0.8) 0.2 (0.8) 0.1 (0.4) 0.1 (0.3)
MO 0.1 (0.3) 0.3 (0.8) 0.3 (0.9) 0.04 (0.2) 0.1 (0.6) 0.0 (0.0)
P 0.180 0.612 0.648 0.566 0.247 0.232
Drowsiness
MO-PR 0.6 (0.7) 1.1 (0.9)* 0.9 (0.8) 0.9 (1.0) 0.5 (0.9) 0.7 (0.9)
MO 0.3 (0.6) 0.5 (0.7)* 0.5 (0.8) 0.4 (0.7) 0.4 (0.6)* 0.4 (0.8)
P 0.105 0.041 0.069 0.060 0.795 0.195
Confusion
MO-PR 0.4 (0.8) 0.5 (0.9) 0.3 (0.6)w 0.2 (0.5) 0.3 (0.7) 0.3 (0.6)
MO 0.1 (0.3) 0.1 (0.3) 0.1 (0.3) 0.1 (0.3) 0.1 (0.4) 0.2 (0.7)
P 0.333 0.080 0.342 0.522 0.425 0.331
Dry mouth
MO-PR 1.2 (1.1) 1.3 (0.9) 1.5 (1.1) 1.3 (1.2) 1.3 (1.1) 1.0 (1.2)
MO 1.1 (1.0) 1.4 (0.9) 1.3 (1.0) 1.2 (1.0) 1.3 (1.2) 1.1 (0.9)
P 0.802 0.772 0.629 0.863 0.915 0.771
Constipation
MO-PR 0.7 (0.9) 0.7 (0.9) 0.9 (1.0) 0.8 (0.7) 0.8 (0.7) 1.1 (0.9)
MO 0.9 (0.8) 1.0 (0.8) 0.8 (0.6) 0.7 (0.5)w 0.6 (0.5)w 0.8 (0.5)
P 0.157 0.178 0.692 0.507 0.522 0.380
Opioid doses
MO-PR 60 70.0 (29.1) 70.6 (31.5) 73.5 (30.4) 80.6 (33.9)wz 85.7 (51.2)w
MO 60 63.7 (15.4) 67.7 (19.2) 67.0 (18.2) 71.8 (18.7)w 75.4 (18.9)wzy
P — 0.329 0.694 0.361 0.270 0.397
Pregabalin doses
25 113.9 (37.5) 114.7 (38.5) 114.7 (38.5) 115 (37.5) 119.2 (43.4)
OEImg (T0-T8)
MO-PR (14 patients) 0.74 (1.21) — — — —
MO (22 patients) 0.42 (0.67) — — — —
P 0.260 — — — —
OEI mg (T0-T8)
MO-PR (14 patients) 1.23 (2.02) — — — —
MO (22 patients) 0.70 (1.11) — — — —
P 0.270 — — — —
Data are expressed as mean (SD).
*P<0.05 versus T0.
wP<0.05 versus W1.
zP<0.05 versus W2.
yP<0.05 versus W3.
MO indicates the group receiving morphine; MO-PR, group receiving both morphine and pregabalin doses.
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and morphine produce better analgesic eﬀects in chronic
pain.23 In volunteers, gabapentinoids have been shown to
enhance morphine analgesia.24 Pregabalin and morphine
signiﬁcantly reduced the area of secondary hyperalgesia.25
Moreover, gabapentinoids reverse microglial activation in
the spinal cord.26 Pregabalin may also provide beneﬁts to
morphine analgesia without the danger of enhanced de-
pendence liability.27
The present study was the ﬁrst presenting data
regarding the use of pregabalin added to morphine in ad-
vanced cancer pain. It was preferred to use a ﬂexible ap-
proach in dosing pregabalin, avoiding a rigid protocol, to
better reproduce the clinical setting and to extrapolate this
information in clinical practice. It has been reported that
the important methodological features that appeared to be
feasible to reproduce data gathered from clinical trials in
clinical practice were slow titration and ﬂexible dosing.28
Data from the present study, however, did not conﬁrm
that pregabalin in doses of about 100mg/d oﬀers speciﬁc an-
algesic beneﬁts to patient receiving morphine for chronic cancer
pain. No diﬀerences in the decrease in pain intensity after
starting similar doses of morphine were observed in patients
who received pregabalin added to morphine therapy. In addi-
tion, despite a “ﬂexible use” of pregabalin with a chance to
change doses to limit the occurrence of adverse eﬀects, ac-
cording to recent suggestions,28 drowsiness was more intense in
patients receiving pregabalin after 1 week of treatment. This
eﬀect, however, tended to disappear with the continuation of
the treatment. In addition, the intensity of nausea was higher in
patients receiving pregabalin at W8, although this late eﬀect
could be attributed to other concomitant causes.
Of interest, opioid doses did not diﬀer between groups
and OEIs used to monitor the dose escalation of morphine
in time. Finally, no diﬀerences in BPI and quality of life were
found, despite a positive trend in both groups in general.
Data from this study cannot exclude the fact that
pregabalin would be more eﬀective under more speciﬁc
conditions such as neuropathic pain. Previous controlled
studies of the parent drug have shown some eﬃcacy of ga-
bapentin in neuropathic cancer pain,2,4 and it is likely that
pregabalin may reproduce similar eﬀects. Unfortunately, a
subgroup analysis of patients with “deﬁnite” neuropathic
TABLE 2. Data on Quality of Life and BPI in the 2 Groups (MO-PR and MO) Before Starting Morphine (T0), at Weekly Intervals (W1, W2,
W3, W4), and After 8 Weeks
T0 W1 W2 W3 W4 W8
N points
MO-PR 18 18 17 17 16 14
MO 30 30 30 30 28 22
QoL Spitz
MO-PR 6.1 (1.8) 6.3 (1.4) 6.9 (1.1) 6.7 (2.0) 6.6 (2.1) 7.1 (1.5)
MO 5.4 (2.0) 6.2 (1.3)* 6.6 (1.5)*w 6.7 (1.6)* 6.7 (1.8)* 7.0 (1.1)*
P 0.333 0.775 0.826 0.865 0.920 0.756
BPI General activity
MO-PR 6.7 (2.7) 4.2 (2.5)* 4.3 (2.5)* 4.5 (3.0)* 4.2 (2.0)* 2.9 (2.4)*
MO 6.8 (1.8) 4.9 (1.9)* 4.5 (1.9)* 4.1 (1.8)*wz 3.5 (1.8)*wz 3.7 (1.7)*w
P 0.866 0.369 0.603 0.726 0.340 0.199
BPI Mood
MO-PR 6.7 (2.3) 5.1 (2.5)* 3.8 (2.9)* 3.8 (3.3)* 3.5 (2.5)* 2.5 (2.7)*
MO 6.6 (2.1) 4.4 (1.9)* 4.3 (2.0)* 3.9 (1.9)*w 3.4 (1.7)*wz 3.3 (1.5)*wz
P 0.728 0.230 0.450 0.589 0.988 0.314
BPI Walking
MO-PR 5.2 (3.6) 4.3 (3.5) 3.5 (3.6) 3.7 (3.2) 3.8 (2.8) 3.2 (3.1)
MO 6.0 (2.4) 4.1 (1.9)* 3.8 (1.9)* 3.6 (2.1)*w 2.8 (1.5)*wzy 2.9 (1.4)*wz
P 0.391 0.929 0.253 0.772 0.420 0.662
BPI Working activity
MO-PR 6.7 (3.0) 4.7 (3.4)* 3.5 (3.0)* 3.7 (3.5)* 4.3 (3.2)* 3.2 (2.6)*
MO 6.6 (2.4) 4.7 (2.3)* 4.1 (2.1)* 4.1 (2.4)* 3.2 (1.7)*w 3.4 (1.7)*w
P 0.760 0.886 0.421 0.453 0.449 0.520
BPI Relationship with other persons
MO-PR 5.1 (3.4) 3.7 (3.1)* 3.1 (3.0)* 2.7 (3.3)* 3.1 (2.9)* 1.9 (2.6)*
MO 5.0 (2.5) 3.3 (2.3)* 2.8 (1.9)* 3.1 (2.6)* 1.9 (1.6)*wzy 2.0 (1.4)*wz
P 0.667 0.528 0.826 0.372 0.371 0.349
BPI Sleep
MO-PR 6.0 (2.9) 4.3 (3.7)* 2.4 (2.7)*w 2.7 (3.0)* 3.1 (3.0)* 3.4 (3.1)*
MO 5.2 (2.4) 2.7 (2.2)* 2.6 (1.9)* 2.4 (1.9)* 1.6 (1.5)*wzy 1.7 (1.5)*wzy
P 0.380 0.215 0.445 0.939 0.208 0.163
BPI Pleasure to live
MO-PR 6.4 (3.0) 5.2 (3.1)* 3.2 (3.1)*w 3.5 (2.9)*w 3.6 (2.5)*w 3.1 (2.2)*w
MO 5.4 (2.5) 3.9 (2.1)* 3.9 (1.9)* 3.8 (1.9)* 3.2 (1.9)*wzy 2.9 (1.7)*wzy
P 0.116 0.089 0.314 0.562 0.485 1.0
Data are expressed as mean (SD).
*P<0.05 versus T0.
wP<0.05 versus W1.
zP<0.05 versus W2.
yP<0.05 versus W3.
BPI indicates Brief Pain Inventory; MO, group receiving morphine; MO-PR, group receiving both morphine and pregabalin doses.
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pain was unreliable for the lower number of patients, also
because of the large number of dropouts. Thus, at the mo-
ment, no information exists supporting this hypothesis. Sim-
ilarly, a possible eﬀect on pain associated with bone metastases
cannot be excluded. Alternately, higher doses could possibly
be more eﬀective, although this approach may produce more
adverse eﬀects.
This study has considerable limitations and this in-
formation should be taken cautiously. The principal
weaknesses of this study include the relatively small size of
the sample. The sample power dropped to 60% at the end of
study, limiting the statistical validity. Moreover, the dropout
rate was not equally distributed in the 2 groups, despite an
appropriate randomization. Studies with drugs used for rel-
atively prolonged periods of time are very diﬃcult to per-
form, particularly if patients are then followed up by phone
interviews and visits at the outpatient clinic. The absence of
some diﬀerences does not constitute a claim for equivalence
between the treatments, because of the inevitable number of
dropouts. However, the dropout rate reported in this study
was consistent with that observed in longitudinal studies of
advanced cancer patients and reﬂects the diﬃculties in per-
forming controlled trials in this population.29 Finally, the
choice of not blinding the study was directed by the need to
reproduce a daily clinical scenario allowing the therapeutic
ﬂexibility needed to reproduce what happens in the daily
activity and to avoid any inﬂuence from any economical
support from pharmaceutical industries.
In conclusion, the use of low doses of pregabalin added
to morphine therapy in advanced cancer patients does not
seem to provide advantageous analgesic eﬀects. Further
studies with appropriate design should explore whether
pregabalin could exert an analgesic eﬀect in patients with
speciﬁc pain conditions, such as neuropathic pain or in-
cident bone pain, or with a diﬀerent dosing protocol.
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